Peter Connick Selected Research

Peter Connick Research Topics

5	Multiple Sclerosis 10/2022 - 03/2011
4	Relapsing-Remitting Multiple Sclerosis 07/2022 - 01/2021
4	Chronic Progressive Multiple Sclerosis 07/2022 - 01/2015
2	Exanthema (Rash) 01/2021 - 02/2012
1	Neuralgia (Stump Neuralgia) 07/2022
1	Pain (Aches) 07/2022
1	Neutropenia 01/2021
1	Hypothyroidism 01/2021
1	Lung Neoplasms (Lung Cancer) 01/2020
1	Heart Diseases (Heart Disease) 01/2020
1	Sudden Death 01/2020
1	Thrombosis (Thrombus) 01/2020
1	Obesity 01/2020
1	Tauopathies 01/2019
1	Disease Progression 01/2018
1	Hypothermia 06/2015
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2015
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 08/2014
1	Bacterial Infections (Bacterial Infection) 02/2012
1	Ischemic Stroke 10/2010

4	Neuroprotective AgentsIBA 07/2022 - 01/2015
2	Bexarotene (LGD1069)FDA Link 10/2022 - 01/2021
2	Amiloride (Midamor)FDA LinkGeneric 07/2022 - 01/2020
2	Fluoxetine (Prozac)FDA LinkGeneric 07/2022 - 01/2020
2	Riluzole FDA LinkGeneric 07/2022 - 01/2020
1	Retinaldehyde (Retinal)IBA 01/2022
1	Retinoid X Receptors (Retinoid X Receptor)IBA 01/2021
1	LipopolysaccharidesIBA 01/2019
1	Cold Shock Proteins and PeptidesIBA 06/2015
1	LipidsIBA 10/2010
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2010